These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 27840326)

  • 1. Safety and efficacy of a bioabsorbable polymer-coated, everolimus-eluting coronary stent in patients with diabetes: the EVOLVE II diabetes substudy.
    Kereiakes DJ; Meredith IT; Masotti M; Carrié D; Moreno R; Erglis A; Mehta SR; Elhadad S; Berland J; Stein B; Airaksinen J; Jobe RL; Reitman A; Janssens L; Christen T; Dawkins KD; Windecker S
    EuroIntervention; 2017 Mar; 12(16):1987-1994. PubMed ID: 27840326
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical Outcomes Following Implantation of Thin-Strut, Bioabsorbable Polymer-Coated, Everolimus-Eluting SYNERGY Stents.
    Kereiakes DJ; Windecker S; Jobe RL; Mehta SR; Sarembock IJ; Feldman RL; Stein B; Dubois C; Grady T; Saito S; Kimura T; Underwood P; Allocco DJ; Meredith IT
    Circ Cardiovasc Interv; 2019 Sep; 12(9):e008152. PubMed ID: 31451014
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent: the EVOLVE II Randomized Trial.
    Kereiakes DJ; Meredith IT; Windecker S; Lee Jobe R; Mehta SR; Sarembock IJ; Feldman RL; Stein B; Dubois C; Grady T; Saito S; Kimura T; Christen T; Allocco DJ; Dawkins KD
    Circ Cardiovasc Interv; 2015 Apr; 8(4):. PubMed ID: 25855680
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents in patients with ST-segment elevation myocardial infarction (BIOSTEMI): a single-blind, prospective, randomised superiority trial.
    Iglesias JF; Muller O; Heg D; Roffi M; Kurz DJ; Moarof I; Weilenmann D; Kaiser C; Tapponnier M; Stortecky S; Losdat S; Eeckhout E; Valgimigli M; Odutayo A; Zwahlen M; Jüni P; Windecker S; Pilgrim T
    Lancet; 2019 Oct; 394(10205):1243-1253. PubMed ID: 31488372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultrathin strut biodegradable polymer sirolimus-eluting stent versus durable polymer everolimus-eluting stent for percutaneous coronary revascularisation (BIOSCIENCE): a randomised, single-blind, non-inferiority trial.
    Pilgrim T; Heg D; Roffi M; Tüller D; Muller O; Vuilliomenet A; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Fahrni T; Moschovitis A; Noble S; Eberli FR; Wenaweser P; Jüni P; Windecker S
    Lancet; 2014 Dec; 384(9960):2111-22. PubMed ID: 25189359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomised comparison of biodegradable polymer- and permanent polymer-coated platinum-chromium everolimus-eluting coronary stents in China: the EVOLVE China study.
    Han Y; Liu H; Yang Y; Zhang J; Xu K; Fu G; Su X; Jiang T; Pang W; Chen J; Yuan Z; Li H; Wang H; Hong T; Liu H; Sun F; Allocco DJ; Zhang M; Dawkins KD
    EuroIntervention; 2017 Nov; 13(10):1210-1217. PubMed ID: 28741576
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bioresorbable polymer sirolimus-eluting coronary stent compared with permanent polymer everolimus-eluting coronary stent implantation for treatment of small vessel coronary artery disease: CENTURY II trial.
    Wöhrle J; Markovic S; Rottbauer W; Muramatsu T; Kadota K; Vázquez-González N; Odenstedt J; Serra A; Antoniucci D; Varenne O; Saito S; Wijns W
    EuroIntervention; 2016 Jun; 12(2):e167-74. PubMed ID: 27290676
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary endpoint results of the EVOLVE trial: a randomized evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting coronary stent.
    Meredith IT; Verheye S; Dubois CL; Dens J; Fajadet J; Carrié D; Walsh S; Oldroyd KG; Varenne O; El-Jack S; Moreno R; Joshi AA; Allocco DJ; Dawkins KD
    J Am Coll Cardiol; 2012 Apr; 59(15):1362-70. PubMed ID: 22341736
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A randomised comparison of a novel abluminal groove-filled biodegradable polymer sirolimus-eluting stent with a durable polymer everolimus-eluting stent: clinical and angiographic follow-up of the TARGET I trial.
    Gao RL; Xu B; Lansky AJ; Yang YJ; Ma CS; Han YL; Chen SL; Li H; Zhang RY; Fu GS; Yuan ZY; Jiang H; Huo Y; Li W; Zhang YJ; Leon MB;
    EuroIntervention; 2013 May; 9(1):75-83. PubMed ID: 23685298
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial.
    Smits PC; Hofma S; Togni M; Vázquez N; Valdés M; Voudris V; Slagboom T; Goy JJ; Vuillomenet A; Serra A; Nouche RT; den Heijer P; van der Ent M
    Lancet; 2013 Feb; 381(9867):651-60. PubMed ID: 23374650
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent.
    Meredith IT; Verheye S; Weissman NJ; Barragan P; Scott D; Valdés Chávarri M; West NE; Kelbæk H; Whitbourn R; Walters DL; Kubica J; Thuesen L; Masotti M; Banning A; Sjögren I; Stables RH; Allocco DJ; Dawkins KD
    EuroIntervention; 2013 Jul; 9(3):308-15. PubMed ID: 23872647
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biolimus-eluting versus everolimus-eluting stents in coronary artery disease: a pooled analysis from the NEXT (NOBORI biolimus-eluting versus XIENCE/PROMUS everolimus-eluting stent) and COMPARE II (Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent) randomised trials.
    Vlachojannis GJ; Puricel S; Natsuaki M; Morimoto T; Smits PC; Kimura T
    EuroIntervention; 2017 Mar; 12(16):1970-1977. PubMed ID: 27802927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodegradable polymer sirolimus-eluting stents versus durable polymer everolimus-eluting stents for primary percutaneous coronary revascularisation of acute myocardial infarction.
    Pilgrim T; Piccolo R; Heg D; Roffi M; Tüller D; Vuilliomenet A; Muller O; Cook S; Weilenmann D; Kaiser C; Jamshidi P; Khattab AA; Taniwaki M; Rigamonti F; Nietlispach F; Blöchlinger S; Wenaweser P; Jüni P; Windecker S
    EuroIntervention; 2016 Dec; 12(11):e1343-e1354. PubMed ID: 26690319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and efficacy of the bioabsorbable polymer everolimus-eluting stent versus durable polymer drug-eluting stents in high-risk patients undergoing PCI: TWILIGHT-SYNERGY.
    Baber U; Chandiramani R; Mehta SR; Sartori S; Zhang Z; Claessen BE; Briguori C; Sharma S; Dangas G; Mehran R
    Catheter Cardiovasc Interv; 2021 Jan; 97(1):63-71. PubMed ID: 32406998
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Third-generation zotarolimus-eluting and everolimus-eluting stents in all-comer patients requiring a percutaneous coronary intervention (DUTCH PEERS): a randomised, single-blind, multicentre, non-inferiority trial.
    von Birgelen C; Sen H; Lam MK; Danse PW; Jessurun GA; Hautvast RW; van Houwelingen GK; Schramm AR; Gin RM; Louwerenburg JW; de Man FH; Stoel MG; Löwik MM; Linssen GC; Saïd SA; Nienhuis MB; Verhorst PM; Basalus MW; Doggen CJ; Tandjung K
    Lancet; 2014 Feb; 383(9915):413-23. PubMed ID: 24183564
    [TBL] [Abstract][Full Text] [Related]  

  • 16. BIOFLOW-III satellite-One-year clinical outcomes of diabetic patients treated with a biodegradable polymer sirolimus-eluting stent and comprehensive medical surveillance.
    Kornowski R; Roguin A; Danenberg H; Assa HV; Abergel E; Rozenbaum E; Guetta V; Landes U; Jabara R; Merdler A; Segev A; Mosseri M; Assali A
    Cardiovasc Revasc Med; 2017; 18(5):338-343. PubMed ID: 28302466
    [TBL] [Abstract][Full Text] [Related]  

  • 17. First-in-human evaluation of a bioabsorbable polymer-coated sirolimus-eluting stent: imaging and clinical results of the DESSOLVE I Trial (DES with sirolimus and a bioabsorbable polymer for the treatment of patients with de novo lesion in the native coronary arteries).
    Ormiston J; Webster M; Stewart J; Vrolix M; Whitbourn R; Donohoe D; Knape C; Lansky A; Attizzani GF; Fitzgerald P; Kandzari DE; Wijns W
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1026-34. PubMed ID: 24055443
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of diabetes on the benefits from everolimus-eluting stent as compared to first-generation drug-eluting stent in patients with ST elevation myocardial infarction.
    De Luca G; Sauro R; Capasso M; Lanzillo T; Manganelli F; Carbone G; Lanni F; Pagliuca MR; Palmieri V; Serino V; Rosato G; Suryapranata H; Di Lorenzo E
    Diab Vasc Dis Res; 2015 Sep; 12(5):306-14. PubMed ID: 26150193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final five-year clinical outcomes in the EVOLVE trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent.
    Meredith IT; Verheye S; Dubois C; Dens J; Farah B; Carrié D; Walsh S; Oldroyd K; Varenne O; El-Jack S; Moreno R; Christen T; Allocco DJ
    EuroIntervention; 2018 Apr; 13(17):2047-2050. PubMed ID: 28923786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A randomized comparison of novel bioresorbable polymer sirolimus-eluting stent and durable polymer everolimus-eluting stent in patients with acute coronary syndromes: The CENTURY II high risk ACS substudy.
    Jiménez VA; Iñiguez A; Baz JA; Valdés M; Ortiz A; Vuilliomenet A; Mainar V; Dudek D; Banai S; Tüller D; Bonnet JL; De Miguel A; Bastos G; Wijns W; Saito S
    Cardiovasc Revasc Med; 2016 Sep; 17(6):355-61. PubMed ID: 27156201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.